🇺🇸 FDA
Patent

US 11844769

Use of cysteamine and derivatives thereof to suppress tumor metastases

granted A61KA61K31/145A61K45/06

Quick answer

US patent 11844769 (Use of cysteamine and derivatives thereof to suppress tumor metastases) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/145, A61K45/06, A61K9/0053, A61K9/28